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respectively 24 months since occurrence of cranial disease manifesta-
tion in line with a considerable quality of life improvement asks to 
investigate more systematically the best use of targeted therapies after 
whole brain irradiation.
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Purpose: EGFR mutations deﬁne a subset of NSCLC with sensitivity 
to geﬁtinib or erlotinib. However, all EGFR mutations are not equal 
and may have different predictive and prognostic value. In this study 
we compared classical “hot spot” and “rare” EGFR mutations in terms 
of response to 1st line chemotherapy and overall survival in a cohort of 
patients with advanced NSCLC.
Patients and Methods: Tumor samples were formalin ﬁxed parafﬁn-
embedded tissues that were microdissected to achieve purity 80% in 
cancer cells. EGFR mutations were analyzed by DNA sequencing of 
exons 18 to 21 in both forward and reverse directions in PCR products 
from tumor genomic DNA. 
Results: Of the 169 patients assessable for mutation detection we 
found 12 (7%) positive for classical “hot spot” (G719D, Del 19, 
E746V, L747S, L858R) EGFR mutations and 34 (20%) positive for 
“rare” EGFR mutations. Classical but not rare mutations were associ-
ated with female gender and never smoking history (P=0.002; P<0.001 
and P=0.637; P=0.402, respectively). However, the histological type 
had no signiﬁcant association with either type of EGFR mutations 
(P=0.520 and P=0.260, respectively).
Response rates to ﬁrst-line chemotherapy were signiﬁcantly higher 
in patients bearing classical mutations (60%) but not in those with 
rare EGFR mutations (29%) as compared with patients with wild-
type EGFR (20.4%) (p=0.005 and p=0.311, respectively). Time to 
tumor progression was 65 weeks, 22 weeks and 33 weeks for patients 
with classical mutations, rare EGFR mutations and wild type EGFR, 
respectively (p=0.165 and p=0.327 as compared to wild type). Overall 
survival was longer in patients bearing classical mutations (p=0.006) 
but not in those with rare mutations (p=0.843) as compared to patients 
with wild type EGFR.
Conclusions: Different EGFR mutation patterns are associated with 
higher response to ﬁrst-line chemotherapy and longer overall survival 
in patients with advanced NSCLC. 
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Background: EGFR mutations in non-small-cell lung cancer (NSCLC) 
are associated with sensitivity to geﬁtinib and erlotinib. However, the 
correlation of EGFR mutation status between primary tumor and me-
tastases is not established. To investigate this, we analyzed 18 patients 
with paired samples of primary and metastatic NSCLC.
Methods: Tumor metastases include adrenal gland, liver, bone, brain, 
lung, skin and thoracic wall. All tumor samples were formalin ﬁxed 
parafﬁn-embedded tissues. Exons 18, 19, 20 and 21 of the EGFR were 
ampliﬁed by PCR and the products were directly sequenced on an ABI 
3100 Avant genetic analyzer. All mutations were conﬁrmed by sequenc-
ing in both directions and by an independent PCR ampliﬁcation.
Results: In 12 cases there was concordance between the primary tumor 
and the corresponding metastases, with EGFR status determined as 
wild type. Discordance was observed in six cases (33.3%): in three 
cases EGFR was mutated only in the primary tumor, while in two cases 
EGFR mutations were found only in metastases. Finally, in one patient 
the metastases had an additional mutation besides that of the primary 
tumor. Two out of 18 patients carried the L692P-V717A and T847A 
mutations respectively only in their metastases. The time to tumor 
progression (TTP) in 1st line chemotherapy was 29 weeks for the 
patient carrying the double mutation (L692P-V717A) and 307 weeks 
for the patient carrying the T847A mutation. Seven out of 18 patients 
were treated with geﬁtinib. Three of them had no mutations in both 
the primary and metastatic tumors and the median TTP was 20 weeks. 
Three patients carried the E746V, L692P and G857E mutations, respec-
tively, in their primary tumors but were wild type in their metastases. 
Interestingly, these patients received RTK inhibitors prior to develop-
ing the metastases. The median TTP for them was 59 weeks. The last 
patient who carried the Del 19 in his primary tumor and the Del 19 and 
T790M in his metastases received geﬁtinib before the second surgery 
and exhibited TTP of 80 weeks.
Conclusions: Our ﬁndings suggest a discordance of EGFR mutation 
status between primary tumor and metastases and imply a possible role 
for EGFR mutation analysis of metastases for the treatment of meta-
static NSCLC with RTKIs.
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Background: Geﬁtinib is an effective treatment for chemotherapy-
resistant East Asian NSCLC patients. The efﬁcacy of geﬁtinib in che-
monaive NSCLC patients bearing different types of EGFR mutations in 
their tumor tissue and who are candidates for standard chemotherapy is 
unclear. It is important to know the precise response rates and response 
durations of geﬁtinib in these patients in order to compare this novel 
approach with standard chemotherapy. 
